Bio Protocol secured $6.9 million in funding from Maelstrom Fund, Animoca Brands and other investors to advance science using AI and crypto.
Decentralized science (DeSci) platform Bio Protocol secured backing from investors including Maelstrom Fund and Animoca Brands to expand its artificial intelligence-native biotech research framework.
Bio Protocol announced Wednesday that it had raised $6.9 million in funding, reflecting growing interest in decentralized approaches to drug discovery that integrate AI, blockchain and community engagement.
Maelstrom founder Arthur Hayes described Bio Protocol as a potential “category-defining launchpad” for scientific research. “If it works, it’s not just a launchpad – it’s the birth of an AI-native research market,” he said.
